MOTS-c

MOTS-c (Mitochondrial-Derived Peptide)

 

Overview

MOTS-c, a mitochondrial-derived peptide, supports metabolic homeostasis and longevity. It enhances exercise capacity, reduces obesity, and improves conditions like insulin resistance and osteoporosis. Originally linked solely to mitochondrial function, research now shows MOTS-c has systemic effects, influencing cell nucleus activity and circulating in the bloodstream. It has shown significant therapeutic potential in various studies over recent years.

Key Benefits

  • Metabolic Support: Promotes balanced metabolic functions, aiding in weight management and insulin sensitivity.
  • Exercise Enhancement: Improves endurance and exercise capacity by optimizing energy production in muscle cells.
  • Bone Health: Supports bone strength by promoting osteoblast activity and improving bone collagen synthesis.
  • Longevity: Associated with certain genetic markers of longevity in populations with a history of extended lifespan.

Structure

  • Peptide Sequence: Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg
  • Molecular Formula: C101H152N28O22S2
  • Molecular Weight: 2174.64 g/mol

Research Findings

Muscle Metabolism

MOTS-c boosts muscle glucose uptake independently of insulin, enhancing muscle function and growth. It activates the AMPK pathway, aiding glucose transport and reducing age-related insulin resistance in muscle cells.

Fat Metabolism

MOTS-c reduces adipose tissue accumulation by increasing brown fat activity and decreasing fat storage. It prevents adipose inflammation, activating pathways that help reduce insulin resistance and support fat metabolism.

Insulin Sensitivity

MOTS-c is linked to insulin sensitivity in lean individuals, acting as a potential early indicator for insulin resistance. Supplementing MOTS-c may help prevent the onset of diabetes in at-risk individuals.

Osteoporosis

MOTS-c enhances bone strength by promoting type I collagen synthesis in osteoblasts. It regulates the TGF-beta/SMAD pathway, supporting osteoblast development and survival, thus playing a critical role in managing osteoporosis.

Cardiovascular Health

Research shows low MOTS-c levels are associated with endothelial dysfunction. Supplementing MOTS-c has improved endothelial responsiveness and blood vessel health, particularly in cardiovascular conditions.

Longevity and Genetic Influence

Certain genetic variations in MOTS-c, found in long-living populations, suggest an association with extended lifespan. These variations affect mitochondrial function, supporting the theory that MOTS-c may play a role in longevity.

How MOTS-c Works

MOTS-c works by activating the AMPK pathway, crucial for cellular energy regulation. It modulates metabolism, helping the body switch efficiently between using glucose and fat for energy, which supports overall metabolic flexibility.

MOTS-c Research

Muscle Metabolism

Research in mice indicates the MOTS-c can reverse age-dependent insulin resistance in muscles, thereby improving muscle uptake of glucose. It does this by improving skeletal muscle response to AMPK activation, which in turn increases the expression of glucose transporters[1]. It is important to note that this activation is independent of the insulin pathway and thus offers an alternative means of boosting glucose uptake by muscles when insulin is ineffective or in insufficient quantity. The net result is improved muscle function, enhanced muscle growth, and decreased functional insulin resistance.

Fat Metabolism

Research in mice has shown that low levels of estrogen lead to increased fat mass and dysfunction of normal adipose tissue. This scenario increases the risk of developing insulin resistance and, subsequently, the risk of developing diabetes. Supplementing mice with MOTS-c, however, increases brown fat function and reduces the accumulation of adipose tissue. It also appears that the peptide prevents adipose dysfunction and the adipose inflammation that typically precedes insulin resistance[2].

It appears that at least part of the influence that MOTS-c has on fat metabolism is mediated through activation of the AMPK pathway. This well-defined pathway is turned on when cellular energy levels are low and it drives the uptake of both glucose and fatty acids by cells for metabolism. It is also the pathway that is activated in ketogenic diets, like the Atkin’s diet, which promote fat metabolism while protecting lean body mass. MOTS-c targets the methionine-folate cycle, increases AICAR levels, and activates AMPK.

New research suggests that MOTS-c can actually leave the mitochondria and make its way to the nucleus where the peptide can affect nuclear gene expression. Following metabolic stress, MOTS-c has been shown to regulate nuclear genes involved in glucose restriction and antioxidant responses[3

Evidence from mice indicates that MOTS-c, particularly in the setting of obesity, is an important regulator of sphingolipid, monoacylglycerol, and dicarboxylate metabolism. By down-regulating these pathways and increasing beta-oxidation, MOTS-c appears to prevent fat accumulation[4]. Some of these effects are almost certainly mediated via MOTS-c action in the nucleus. Research on MOTS-c has led to a new hypothesis about fat deposition and insulin resistance that is gaining traction in the scientific community and may offer a new means of intervening in the pathophysiology of obesity and diabetes. It appears that dysregulation of fat metabolism in mitochondria may result in a lack of fat oxidation. This leads to higher levels of circulating fat and thus forces the body to boost insulin levels in an effort to clear lipids from the bloodstream. The consequence of this action is increased fat deposition and a homeostatic change in the body as it adapts to (and becomes resistant to) chronically higher levels of insulin

Insulin Sensitivity

Research measuring MOTS-c levels in insulin sensitive and insulin resistant individuals has shown that the protein is associated with insulin sensitivity only in lean individuals. In other words, MOTS-c appears to be important in the pathogenesis of insulin insensitivity, but not in the maintenance of the condition[6]. Scientists speculate that the peptide maybe a useful means of monitoring pre-diabetic lean individuals and that changes in MOTS-c levels could act as an early warning sign of potential insulin insensitivity. Supplementation with MOTS-c in this setting could help to stave off insulin resistance and thus the development of diabetes. Research in mice thus far has been promising, but more work is needed to understand the full impact of MOTS-c on insulin regulation.

Osteoporosis

MOTS-c appears to play a role in the synthesis of type I collagen by osteoblasts in bone. Research in osteoblast cell lines shows that MOTS-c regulates the TGF-beta/SMAD pathway responsible for the health and survival of osteoblasts. By promoting osteoblast survival, MOTS-c helps to improve type I collagen synthesis and therefore the strength and integrity of bone[7]. Additional research in osteoporosis has revealed that MOTS-c promotes the differentiation of bone marrow stem cells via the same TGF-beta/SMAD pathway. In the study, this directly led to increased osteogenesis (formation of new bone)[8]. Thus, not only does MOTS-c protect osteoblasts and promote their survival, it promotes their development from stem cells as well.

Longevity

Research on MOTS-c has identified a specific change in the peptide that is associated with longevity in certain human populations, such as the Japanese. The change in the MOTS-c gene, in this case, leads to the substitution of a glutamate residue for the lysine that is normally found in position 14 of the protein. It is not clear how this change affects the functional aspects of the protein, but that it does is almost certain as glutamate has radically different properties than lysine and thus would change both the structure and the function of the MOTS-c gene. More research is required to understand how this change affects function, but it is found exclusively in people with Northeast Asian ancestry and is thought to play a role in the exceptional longevity seen in this population[9].

According to Dr. Changhan David Lee, a researcher at the School of Gerontology at USC Leonard Davis, mitochondrial biology holds the keep to extending both lifespan and healthspan in humans. The mitochondria, being the single most important metabolic organelle, is “strongly implicated in aging and age-related diseases.” Until now, dietary restriction offered the only reliable means of affecting mitochondrial function and thus longevity. Peptides like MOTS-c, however, may make it possible to directly impact mitochondrial function in a more profound way.

Heart Health

Research measuring MOTS-c levels in humans undergoing coronary angiography has revealed that patients with lower levels of MOTS-c in the blood have higher levels of endothelial cell dysfunction. Endothelial cells line the inside of blood vessels and are integral to the regulation of blood pressure, blood clotting, and plaque formation. Additional research in rats suggests that while MOTS-c does not directly affect blood vessel responsiveness, it does sensitize endothelial cells to the effects of other signaling molecules, like acetylcholine. Supplementing rats with MOTS-c has been shown to improve endothelial function and improve microvascular and epicardial blood vessel function[10]. MOTS-c is not alone among mitochondria-derived peptides (MDPs) in affecting heart health. Research suggests that at least three MDPs play roles in protecting cardiac cells against stress and inflammation. There is good reason to believe that MDP dysregulation is also an important factor in the development of cardiovascular disease. The peptides may even be important factors in reperfusion injury and, as pointed out above, in endothelial function[11]. MOTS-c exhibits minimal side effects, low oral and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not scale to humans. MOTS-c for sale at Peptide Sciences is limited to educational and scientific research only, not for human consumption. Only buy MOTS-c if you are a licensed researcher.

MOTS-C (mitochondrial open-reading-frame of the 12S rRNA-c) peptide is a novel mitochondria-derived peptide. MOTS-C is a short peptide composed of 16 amino acids, expressed in both tissues and plasma, indicating that the peptide has a cell-specific and hormonal role in the body(1). With the ability to work both as a cell-specific compound and as a hormone, this peptide mainly works by stimulating the AMPK pathway. To date, only two mitochondria-derived peptides (MDPs) have been aggressively studied, Humanin and MOTS-C. When metabolic stress occurs in the body, the MOTS-C peptide is believed to translocate to the cellular nuclei and alter the gene expression. MOTS-C peptide is also released in the bloodstream and is known as “mitochondrial hormone” or simply as “mitokine”.(2,3) The peptide has numerous benefits, including obesity management, increased energy levels, enhanced skeletal muscle metabolism, improved heart health, and possible longevity.

MOTS-C Chemical Structure(4)

Molecular Formula: C101H152N28O22S2
Molecular Weight: 2174.64 g/mol
Other Titles: Mitochondrial-derived peptide MOTS-c, Mitochondrial open reading frame of the 12S rRNA-c

MOTS-C Uses and Effects

Animal research models have indicated multiple benefits from MOTS-C peptide therapy, including increased physical performance, regulated cellular and tissue metabolism, and myoblast adaptation.() Research indicates that these results are mainly dependent on age. As per Joseph C Reynolds et al., “Mitochondria are chief metabolic organelles with strong implications in aging that also coordinate broad physiological functions, in part, using peptides that are encoded within their independent genome.”(5) MOTS-C is endogenously expressed via exercise, and MOTS-C enhances physical activity and cellular metabolism.

Enhanced Muscle Metabolism
With increasing age, skeletal muscles tend to gain insulin resistance leading to decreased glucose uptake. Upon MOTS-C peptide administration, skeletal muscles are stimulated with an improved response toward AMPK activation. As a result, there is increased expression of the glucose transporters. These stimulations lead to improved skeletal muscle metabolism and enhanced skeletal muscle functioning and growth.(1)

Obesity Treatment
MOTS-C peptide triggers the AMPK pathway, which promotes using excess lipids and protects the lean body mass. Research has shown that the MOTS-C peptide can leave the mitochondrial site, translocate to cellular nuclei, and alter gene expression. This action, in turn, alters glucose uptake restriction.(6)
The above is supported by a research study in which the experimental mice were given high-fat food, and only half were treated with MOTS-C peptide. Mice treated with the MOTS-C peptide were lean and more energetic than the rest, further indicating that the peptide prevents fat accumulation and induces glucose uptake via the AMPK pathway.

Osteoporosis
MOTS-C peptide regulates the transforming growth factor (TGF) beta and SMAD pathway, which profoundly affects bone health.(7) This peptide stimulates the SMAD pathway in the osteoblast cells, improving bone health and strength. When studied in bone marrow cells, this compound triggers the differentiation of the stem cells, which leads to bone development. These results demonstrate that the MOTS-C peptide can improve bone strength and health and produce new bones, both of which are critical in treating osteoporosis.

Cardiac Health
MOTS-C peptide does not directly influence the cardiac muscles; instead, it affects the endothelial cells that line the blood vessels inside. These endothelial tissues affect blood pressure and clotting. Studies show that when MOTS-C peptide was administered in mice, it improved the functioning of the endothelial tissues, thereby ameliorating the heart’s overall health.(8)

Insulin Sensitivity
MOTS-C peptide is associated with insulin sensitivity, but only in lean research subjects. The compound is more important in monitoring the development of insulin insensitivity rather than maintaining the condition.(10) The peptide should be used to monitor prediabetic lean subjects, and any change in the MOTS-C peptide level should demonstrate an early diagnosis of insulin insensitivity.

Longevity
Research has suggested that the MOTS-C peptide may be associated with enhanced longevity. The peptide typically contains glutamate residue, but when this is replaced by lysine, the new compound shows a functional change in the compound. Scientists so far are aware that the functionality of the glutamate and lysine group is vastly different, but how this specific structural change affects peptide functionality is yet to be understood. Noriyuki Fuku et al. suggest that there is “a biological link between MOTS-C and extended lifespan through the putative endocrine action of this mitokine. Further mechanistic research is needed to determine the functional significance of polymorphism and the potential influence of MOTS-C in the human aging process.?” (9)

MOTS-c is available for research and laboratory purposes only.

MOTS-c Structure

Sequence: Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg

Molecular Formula: C101H152N28O22S2

Molecular Weight: 2174.64 g/mol PubChem SID: 255386757 CAS Number: 1627580-64-6 Synonyms: Mitochondrial open reading frame of the 12S rRNA-c, MT-RNR1

REFERENCES
  1. Lee C, Kim KH, Cohen P. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radic Biol Med. 2016 Nov;100:182-187. doi: 10.1016/j.freeradbiomed.2016.05.015. Epub 2016 May 20. PMID: 27216708; PMCID: PMC5116416. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5116416/
  2. Zahra Mohtashami et al, MOTS-c, The Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases, International Journal of Molecular Sciences
  3. Lee C, Kim KH, Cohen P. MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism. Free Radic Biol Med. 2016 Nov;100:182-187. doi: 10.1016/j.freeradbiomed.2016.05.015. Epub 2016 May 20. PMID: 27216708; PMCID: PMC5116416. https://pubmed.ncbi.nlm.nih.gov/27216708/
  4. Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benayoun BA, Merry TL, Lee C. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021 Jan 20;12(1):470. https://pubmed.ncbi.nlm.nih.gov/33473109/
  5. Lu H, Wei M, Zhai Y, Li Q, Ye Z, Wang L, Luo W, Chen J, Lu Z. MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction. J Mol Med (Berl). 2019 Apr;97(4):473-485. doi: 10.1007/s00109-018-01738-w. Epub 2019 Feb 6. PMID: 30725119. https://pubmed.ncbi.nlm.nih.gov/30725119/
  6. Kim KH, Son JM, Benayoun BA, Lee C. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metab. 2018 Sep 4;28(3):516-524.e7. doi: 10.1016/j.cmet.2018.06.008. Epub 2018 Jul 5. PMID: 29983246; PMCID: PMC6185997. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6185997/
  7. Hu BT, Chen WZ. MOTS-c improves osteoporosis by promoting osteogenic differentiation of bone marrow mesenchymal stem cells via TGF-β/Smad pathway. Eur Rev Med Pharmacol Sci. 2018 Nov;22(21):7156-7163. doi: 10.26355/eurrev_201811_16247. PMID: 30468456. https://pubmed.ncbi.nlm.nih.gov/30468456/
  8. Qin Q, Delrio S, Wan J, Jay Widmer R, Cohen P, Lerman LO, Lerman A. Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction. Int J Cardiol. 2018 Mar 1;254:23-27. doi: 10.1016/j.ijcard.2017.12.001. Epub 2017 Dec 6. PMID: 29242099. https://pubmed.ncbi.nlm.nih.gov/29242099/
  9. Noriyuki Fuku el al., The mitochondrial-derived peptide MOTS-c: A player in exceptional longevity?, http://dx.doi.org/10.1111/acel.12389.
  10. Che N, Qiu W, Wang JK, Sun XX, Xu LX, Liu R, Gu L. MOTS-c improves osteoporosis by promoting the synthesis of type I collagen in osteoblasts via TGF-β/SMAD signaling pathway. Eur Rev Med Pharmacol Sci. 2019 Apr;23(8):3183-3189. doi: 10.26355/eurrev_201904_17676. PMID: 31081069. https://pubmed.ncbi.nlm.nih.gov/31081069/